Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06409130
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2024-05-07
Brief Title:
Effects of NNC0194-0499 Cagrilintide and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
Effects of NNC0194-0499 Alone and in Combination With Semaglutide of Semaglutide Alone and of Cagrilintide Alone and in Combination With Semaglutide on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will look at the effects of NNC0194-0499 cagrilintide and semaglutide on liver damage and alcohol use in participants with alcoholic liver disease Participants will get NNC0194-0499 semaglutide cagrilintide or dummy medicine in different treatment combinations Which treatment participants get is decided by chance The study will last for about 39 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-508170-28 | OTHER | European Medical Agency EMA | None |
| U1111-1295-6713 | OTHER | None | None |